Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CAP 100

Next Previous
X
Search
Drug Profile

CAP 100

Alternative Names: CAP-100

Latest Information Update: 28 Oct 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Catapult Therapeutics
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; CCR7 receptor antagonists; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Chronic lymphocytic leukaemia

Most Recent Events

  • 28 Oct 2024 No recent reports of development identified for phase-I development in Chronic-lymphocytic-leukaemia(Monotherapy, Second-line therapy or greater) in USA (IV)
  • 10 Sep 2021 Phase-I clinical trials in Chronic lymphocytic leukaemia (Monotherapy, Second-line therapy or greater) in USA (IV) (NCT04704323)
  • 08 Feb 2021 Catapult Therapeutics plans a phase Ia/b trial for Chronic lymphocytic leukaemia (Monotherapy, Second line therapy or greater) in USA in the second quarter of 2021 (NCT04704323)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top